WDNA vs. XPH
Compare and contrast key facts about WisdomTree BioRevolution Fund (WDNA) and SPDR S&P Pharmaceuticals ETF (XPH).
WDNA and XPH are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. WDNA is a passively managed fund by WisdomTree that tracks the performance of the WisdomTree BioRevolution Index. It was launched on Jun 3, 2021. XPH is a passively managed fund by State Street that tracks the performance of the S&P Pharmaceuticals Select Industry Index. It was launched on Jun 19, 2006. Both WDNA and XPH are passive ETFs, meaning that they are not actively managed but aim to replicate the performance of the underlying index as closely as possible.
Performance
WDNA vs. XPH - Performance Comparison
Loading graphics...
WDNA vs. XPH - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
WDNA WisdomTree BioRevolution Fund | 2.99% | 22.68% | -14.18% | -2.07% | -26.29% | -5.27% |
XPH SPDR S&P Pharmaceuticals ETF | -3.32% | 31.60% | 4.94% | 2.97% | -9.83% | -8.12% |
Returns By Period
In the year-to-date period, WDNA achieves a 2.99% return, which is significantly higher than XPH's -3.32% return.
WDNA
- 1D
- 4.08%
- 1M
- -4.89%
- YTD
- 2.99%
- 6M
- 14.31%
- 1Y
- 41.33%
- 3Y*
- 2.41%
- 5Y*
- —
- 10Y*
- —
XPH
- 1D
- 5.32%
- 1M
- -5.56%
- YTD
- -3.32%
- 6M
- 13.19%
- 1Y
- 24.45%
- 3Y*
- 11.04%
- 5Y*
- 2.79%
- 10Y*
- 3.82%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
WDNA vs. XPH - Expense Ratio Comparison
WDNA has a 0.45% expense ratio, which is higher than XPH's 0.35% expense ratio.
Return for Risk
WDNA vs. XPH — Risk / Return Rank
WDNA
XPH
WDNA vs. XPH - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for WisdomTree BioRevolution Fund (WDNA) and SPDR S&P Pharmaceuticals ETF (XPH). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| WDNA | XPH | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.40 | 1.00 | +0.40 |
Sortino ratioReturn per unit of downside risk | 2.06 | 1.47 | +0.59 |
Omega ratioGain probability vs. loss probability | 1.25 | 1.19 | +0.06 |
Calmar ratioReturn relative to maximum drawdown | 3.20 | 1.77 | +1.43 |
Martin ratioReturn relative to average drawdown | 7.58 | 5.52 | +2.06 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| WDNA | XPH | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.40 | 1.00 | +0.40 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | — | 0.14 | — |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | 0.17 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.24 | 0.38 | -0.62 |
Correlation
The correlation between WDNA and XPH is 0.79, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.
Dividends
WDNA vs. XPH - Dividend Comparison
WDNA's dividend yield for the trailing twelve months is around 4.43%, more than XPH's 0.69% yield.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
WDNA WisdomTree BioRevolution Fund | 4.43% | 4.57% | 0.75% | 0.80% | 0.38% | 0.10% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
XPH SPDR S&P Pharmaceuticals ETF | 0.69% | 0.83% | 1.58% | 1.28% | 1.64% | 0.95% | 0.47% | 0.64% | 0.65% | 0.67% | 0.63% | 7.15% |
Drawdowns
WDNA vs. XPH - Drawdown Comparison
The maximum WDNA drawdown since its inception was -58.87%, which is greater than XPH's maximum drawdown of -48.03%. Use the drawdown chart below to compare losses from any high point for WDNA and XPH.
Loading graphics...
Drawdown Indicators
| WDNA | XPH | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -58.87% | -48.03% | -10.84% |
Max Drawdown (1Y)Largest decline over 1 year | -11.70% | -13.15% | +1.45% |
Max Drawdown (5Y)Largest decline over 5 years | — | -31.63% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -35.97% | — |
Current DrawdownCurrent decline from peak | -33.71% | -7.29% | -26.42% |
Average DrawdownAverage peak-to-trough decline | -35.79% | -17.37% | -18.42% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.20% | 5.23% | -0.03% |
Volatility
WDNA vs. XPH - Volatility Comparison
The current volatility for WisdomTree BioRevolution Fund (WDNA) is 8.88%, while SPDR S&P Pharmaceuticals ETF (XPH) has a volatility of 9.49%. This indicates that WDNA experiences smaller price fluctuations and is considered to be less risky than XPH based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| WDNA | XPH | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 8.88% | 9.49% | -0.61% |
Volatility (6M)Calculated over the trailing 6-month period | 18.59% | 16.38% | +2.21% |
Volatility (1Y)Calculated over the trailing 1-year period | 29.63% | 24.72% | +4.91% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 25.17% | 20.56% | +4.61% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 25.17% | 22.22% | +2.95% |